Compare BioNTech SE - ADR (BNTX) vs Annaly Capital Management, Inc. (NLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Annaly Capital Management, Inc. — how do they compare? BioNTech SE - ADR trades at $89.89 (market cap $22.86B), while Annaly Capital Management, Inc. trades at $23 (market cap $16.86B). The key difference: BioNTech SE - ADR is the larger of the two by market cap, and Annaly Capital Management, Inc. pays a 13.04% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | NLY | |
|---|---|---|
Market Cap | $22.86B | $16.86B |
Sector | Health | Financials |
52-Week High | $119.34 | $24.40 |
52-Week Low | $83.89 | $19.47 |
Enterprise Value | $6.53B | — |
Dividend Yield | — | 13.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
NLY trades at $22.53, down 1.44% on the day, with a bullish technical signal from moving averages and strong earnings beats in recent quarters. The stock shows a P/E of 7.27 and P/B of 1.14, trading below the consensus price target of $24.40. Recent news highlights earnings growth potential and a dividend of $0.75 payable in July 2026, supported by a net income margin of 91.17% in 2025.
Outlook remains positive with analyst consensus favoring Buy ratings (57%), though risks include interest rate sensitivity and high leverage. The stock offers value with earnings momentum, but investors should monitor debt levels and Federal Reserve policy impacts on mortgage REITs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Annaly Capital Management, Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.
Read more on NLY →
